Lataa...
Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
Dasatinib is a potent dual Abl/Src inhibitor approved for treatment of Ph-positive leukemias. At a once-daily dose and a relatively short half-life of 3-5 hours, tyrosine kinase inhibition is not sustained. However, transient inhibition of K562 leukemia cells with a high-dose pulse of dasatinib or l...
Tallennettuna:
| Päätekijät: | , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2010
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3038787/ https://ncbi.nlm.nih.gov/pubmed/20111071 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2009.302 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|